Bavarian Nordic cannot exclusively handle production of the company's covid-19 vaccine if and when it is ready for phase III and the subsequent commercialization.
In spite of expansions made in the firm's production apparatus in recent years, the firm lacks the equipment and capacity necessary for fulfilling production in this scale, which Bavarian Nordic Chief Financial Officer Henrik Juuel tells MedWatch in an interview.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.